An application of PEG interferon and a proto-oncogene product targeting inhibitor in synergistic treatment of renal carcinoma. Specifically, provided is use of a combination of active components, the combination of active components comprising the PEG interferon and the proto-oncogene product targeted inhibitor, and the combination being used for preparing a pharmaceutical composition for synergistic treatment of renal carcinoma. The combination of active components can effectively and synergistically inhibit renal carcinoma, and can significantly reduce toxic and side effects, and thus can be widely applied to tumor targeted treatment.

Described herein are methods of protecting and/or promoting proliferation of intestinal epithelium by administering an Interferon (IFN) λ ligand or an IFNλ, receptor agonist to a subject in need thereof. Preferred methods utilising an IFNλ receptor agonist concern preventing or treating a gastrointestinal disease, disorder or condition, such as GVHD, inflammatory bowel disease and autoimmune and therapy-related enterocolitis.

Described herein are methods of protecting and/or promoting proliferation of intestinal epithelium by administering an Interferon (IFN) λ ligand or an IFNλ, receptor agonist to a subject in need thereof. Preferred methods utilising an IFNλ receptor agonist concern preventing or treating a gastrointestinal disease, disorder or condition, such as GVHD, inflammatory bowel disease and autoimmune and therapy-related enterocolitis.

The present invention relates to a pharmaceutical or veterinary composition for its use in preventing and/or treating a MERS-CoV (Middle-East Respiratory Syndrome) coronavirus infection, characterised in that it comprises, in a suitable pharmaceutical vehicle, at least one compound chosen from apigenin and berberine.

The present invention relates to a pharmaceutical or veterinary composition for its use in preventing and/or treating a MERS-CoV (Middle-East Respiratory Syndrome) coronavirus infection, characterised in that it comprises, in a suitable pharmaceutical vehicle, at least one compound chosen from apigenin and berberine.

The present invention relates to a pharmaceutical or veterinary composition for its use in preventing and/or treating a MERS-CoV (Middle-East Respiratory Syndrome) coronavirus infection, characterised in that it comprises, in a suitable pharmaceutical vehicle, at least one compound chosen from apigenin and berberine.

The present disclosure provides, in some aspects, macromonomers of Formula (I), and salts thereof; methods of preparing the macromonomers, and salts thereof; Brush prodrugs (polymers); methods of preparing the Brush prodrugs; compounds of Formula (II); conjugates of Formula (III), and salts thereof; pharmaceutical compositions comprising a Brush prodrug, or a conjugate or a salt thereof; kits comprising: a macromonomer or a salt thereof, a Brush prodrug, a compound, a conjugate or a salt thereof, or a pharmaceutical composition; methods of using the Brush prodrugs, or conjugates or salts thereof; and uses of the Brush prodrugs, and conjugates or salts thereof. These chemical entities may be useful in delivering pharmaceutical agents to a subject or cell.

The present invention relates to method of treating HBV infection in a human patient, wherein the method comprises administration of a therapeutically effective amount of Compound (I), or a pharmaceutically acceptable salt thereof.

An application of PEG-interferon and a protooncogene product targeting inhibitor in synergistic inhibition of tumors. Specifically, provided is use of an active ingredient combination. The active ingredient combination comprises PEG-interferon and a protooncogene product targeting inhibitor, and the combination is used for preparing a pharmaceutical composition for synergistic treatment of tumors. The active ingredient combination can synergistically inhibit the growth of tumors (especially lung, stomach, breast and liver cancers) effectively, and can significantly reduce toxic and side effects, and therefore can be widely used in targeted therapy of the tumors.

An application of PEG-interferon and a protooncogene product targeting inhibitor in synergistic inhibition of tumors. Specifically, provided is use of an active ingredient combination. The active ingredient combination comprises PEG-interferon and a protooncogene product targeting inhibitor, and the combination is used for preparing a pharmaceutical composition for synergistic treatment of tumors. The active ingredient combination can synergistically inhibit the growth of tumors (especially lung, stomach, breast and liver cancers) effectively, and can significantly reduce toxic and side effects, and therefore can be widely used in targeted therapy of the tumors.